BioPharmCatalyst (A Scientist.com Company)’s Post

#Takeaways: How does X-Chem facilitate covalent drug discovery for partners? The identification of novel covalent ligands for therapeutic purposes has long depended on serendipity. At X-Chem, we design highly efficient methods to identify new chemical equity towards targets of interest, aiming to improve the safety, potency, and selectivity of the outcome. You can learn more in our covalent drug discovery webinar: https://lnkd.in/gSa6pPw4 Selected success examples: - Bfl1 reversible inhibitor: https://lnkd.in/eZsxQPmr - WDR91 inhibitor: https://lnkd.in/eJihD4bn - BTK inhibitors: https://lnkd.in/dDeUYkj #DrugDiscovery #CovalentDrug #HitID #LeadOptimization #Pharma #Biotech #DrugDevelopment #Technology

Biotage’s 2023 Annual Report is out now bringing together last year’s key activities and highlights. ✔ Astrea Bioseparations, a high-growth biological chromatography solutions provider, became part of Biotage. This strategic acquisition marks a significant expansion for Biotage into the thriving bioprocessing sector.   ✔ The share of Biologics and Advanced Therapeutics product area went up to 24% of our total revenue in 2023.   ✔ Our commitment to advancing our customers’ peptide and flash purification workflows resulted in the launch of several solutions to drive efficiency and improved outcomes.   ✔ In alignment with the new European Standards and Directives, we have performed a double materiality analysis that looks at our sustainability impact long and short term.   Explore more insights in the full report at https://lnkd.in/gqwGWCdE #biotage #annualreport2023 #pharma #biopharma

Thoughts on this? >> Alumis closes a $259M Series C, setting sights on PhIII trials for TYK2 inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #healthcare #biotech

Thoughts on this? >> Alumis closes a $259M Series C, setting sights on PhIII trials for TYK2 inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

Considering a modification to your antibody framework? MAbSilico specializes in humanizing the sequence, enhancing its affinity for the target, refining cross-species binding, and adjusting specificity. 🌐 Explore more: 🌐 mabsilico.com #BioTechs #Pharma #Insilico

One of the key advantages of MAbSilico's approach lies in its ability to rapidly sift through vast libraries of antibodies, characterizing their properties and identifying promising candidates in a fraction of the time required by traditional methods. Learn more today! 🌐 mabsilico.com #BioTechs #Pharma #Insilico

Read about this week’s global biosimilar developments in the #BioBlast by Pearce IP….

D is the first letter in DCAT. It is the second letter in CDMO and Advisor. It is also the antepenultimate letter in Monday, Tuesday, Wednesday, and Thursday. These are the four days I ‘ll be in NYC for DCAT pitching various active and ongoing projects, from promoting the launch of the CDMO Advisor beta webpage, to pitching Vectron Biosolutions AS, Project Insulin, Drug Biologics Consulting, CellViva, and more! I am eager to talk to y’all. There are many ways to reach out to us. The easiest is: messaging @ 908-666-7664; or email @ bestupinan@drugbiologics.com; or DM @ LinkedIn Messaging. #dcatweek #cdmo #NYC #biotechnology

Thoughts on this? >> Private Danish iron deficiency biotech to buy G1 Therapeutics for $405M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #biotech #productmarketing

This week's Pearce IP #BioBlast  features the following (and more!):   - #bevacizumab / #trastuzumab: Biocon Biologics and Sandoz partner in Australia for biosimilars  - #denosumab: Phase III data on Mabwell (Shanghai) Bioscience Co., Ltd.’s biosimilar to Amgen’s #Xgeva®  - #infliximab: Celltrion Inc to supply #Yuflyma® to Norway  - #ustekinumab: Rani Therapeutics PhI data for RT-111, oral form of Celltrion Inc’s CT-P43 biosimilar  - #tulmimetostat / #pelabresib: Novartis to buy MorphoSys AG for €2.7B   - #rituximab: study shows promise for managing AIBD Read more: https://lnkd.in/gY2PNktN #bioblast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma #lifesciences #femalefounder